Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke The EXTEND-IA TNK Part 2 Randomized Clinical Trial
Bruce CV Campbell, Peter J Mitchell, Leonid Churilov, Nawaf Yassi, Timothy J Kleinig, Richard J Dowling, Bernard Yan, Steven J Bush, Vincent Thijs, Rebecca Scroop, Marion Simpson, Mark Brooks, Hamed Asadi, Teddy Y Wu, Darshan G Shah, Tissa Wijeratne, Henry Zhao, Fana Alemseged, Felix Ng, Peter Bailey Show all
JAMA | AMER MEDICAL ASSOC | Published : 2020
Importance: Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase. Objective: To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke. Design, Setting, and Participants: Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke d..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by National Heart Foundation of Australia
EXTEND-IA TNK part 2 was supported by grants from the National Health and Medical Research Council of Australia (1043242, 1035688, 1113352, 1111972) and the National Heart Foundation of Australia (100782). The Victorian government provided infrastructure funding. iSchemaView provided a research version of the RAPID software free of charge for the trial.